 Numerous publications have shown that in vivo delivery systems are very promising and are diverse in characteristics, allowing numerous applications.The nanoparticle delivery system shows the most promise yet this method presents additional challenges in the scale-up of the manufacturing process, such as the need for tightly controlled mixing processes to achieve consistent quality of the drug product.The table below shows different drugs using RNA interference and what their phases and status was in clinical trials as of 2013.